- Home
- CDNA vs UPB Comparison
CDNA vs UPB Comparison
Compare CDNA & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- UPB
- Stock Information
- Founded
- CDNA 1998
- UPB 2021
- Country
- CDNA United States
- UPB United States
- Employees
- CDNA N/A
- UPB N/A
- Industry
- CDNA Medical Specialities
- UPB
- Sector
- CDNA Health Care
- UPB
- Exchange
- CDNA Nasdaq
- UPB NYSE
- Market Cap
- CDNA 1.1B
- UPB 1.0B
- IPO Year
- CDNA 2014
- UPB 2024
- Fundamental
- Price
- CDNA $23.34
- UPB $16.98
- Analyst Decision
- CDNA Buy
- UPB Strong Buy
- Analyst Count
- CDNA 8
- UPB 4
- Target Price
- CDNA $27.17
- UPB $56.50
- AVG Volume (30 Days)
- CDNA 642.2K
- UPB 464.5K
- Earning Date
- CDNA 02-26-2025
- UPB 02-14-2025
- Dividend Yield
- CDNA N/A
- UPB N/A
- EPS Growth
- CDNA N/A
- UPB N/A
- EPS
- CDNA N/A
- UPB N/A
- Revenue
- CDNA $312,775,000.00
- UPB $2,207,000.00
- Revenue This Year
- CDNA $19.85
- UPB N/A
- Revenue Next Year
- CDNA $11.34
- UPB N/A
- P/E Ratio
- CDNA N/A
- UPB N/A
- Revenue Growth
- CDNA 5.26
- UPB 82.10
- 52 Week Low
- CDNA $7.42
- UPB $14.97
- 52 Week High
- CDNA $34.84
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- CDNA 56.42
- UPB N/A
- Support Level
- CDNA $20.35
- UPB N/A
- Resistance Level
- CDNA $21.68
- UPB N/A
- Average True Range (ATR)
- CDNA 1.10
- UPB 0.00
- MACD
- CDNA 0.19
- UPB 0.00
- Stochastic Oscillator
- CDNA 99.09
- UPB 0.00
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.